# Study of AZD0754 in Participants With Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct06267729/  
OnCo record `nct06267729` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD0754 in prostate cancer, run by AstraZeneca, now recruiting.

## Summary

Study of AZD0754 in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT06267729 by AstraZeneca, with 60 participants planned, started 2024-03-12 and due to reach its primary completion in 2026-11-24. Interventions recorded: AZD0754 and AZD2287.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06267729
- Phase: 1/2
- Setting: A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO
- Sponsor: AstraZeneca
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06267729: https://clinicaltrials.gov/study/NCT06267729

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06267729.json